Alzheimer’s Treatment Centers of America
This organization specializes in integrated, science-based treatment and diagnostics for Alzheimer’s, dementia, and cognitive decline. Utilizing a precision medicine approach, the center combines advanced AI analysis, biomarker-driven planning, and multimodal therapies including brain imaging, neurocognitive testing, and over 50 clinical and supportive treatment modalities. The care model addresses both the root causes and neuropsychiatric aspects of cognitive impairment, delivered by a multidisciplinary team with expertise in functional, regenerative, and collaborative behavioral medicine.
Industries
N/A
Alzheimer’s Treatment Centers of America
Products
Radiation-free, color brain imaging system for real-time detection of amyloid plaque and inflammation.
System combining EEG brainwave analysis with computerized cognitive performance testing for dementia subtype identification and progress tracking.
Investigational monoclonal antibody engineered to reduce neuroinflammation and protein aggregation in Alzheimer's disease.
Non-invasive clinical device for delivery of sound and vibration stimuli to promote restorative deep sleep in cognitive disorder patients.
Radiation-free, color brain imaging system for real-time detection of amyloid plaque and inflammation.
System combining EEG brainwave analysis with computerized cognitive performance testing for dementia subtype identification and progress tracking.
Investigational monoclonal antibody engineered to reduce neuroinflammation and protein aggregation in Alzheimer's disease.
Non-invasive clinical device for delivery of sound and vibration stimuli to promote restorative deep sleep in cognitive disorder patients.
Services
Comprehensive assessment using neuroimaging, cognitive performance testing, and biomarker analysis.
Implementation of precision medicine protocols driven by advanced AI analytics to address underlying causes of cognitive impairment.
Blood plasma filtration procedure for removal of toxins, amyloid-beta and inflammatory agents to support neurological health.
Administration of a humanized monoclonal antibody targeting neuroinflammatory pathways as part of clinical trial or expanded access program.
Intravenous delivery of vitamins, antioxidants, and nutrients to support brain function and cellular health.
Application of full-spectrum light (red, green, blue, and near-infrared) to modulate inflammation, support cellular repair, circulation, and neurological function.
Comprehensive assessment using neuroimaging, cognitive performance testing, and biomarker analysis.
Implementation of precision medicine protocols driven by advanced AI analytics to address underlying causes of cognitive impairment.
Blood plasma filtration procedure for removal of toxins, amyloid-beta and inflammatory agents to support neurological health.
Administration of a humanized monoclonal antibody targeting neuroinflammatory pathways as part of clinical trial or expanded access program.
Intravenous delivery of vitamins, antioxidants, and nutrients to support brain function and cellular health.
Application of full-spectrum light (red, green, blue, and near-infrared) to modulate inflammation, support cellular repair, circulation, and neurological function.
Expertise Areas
- Clinical trial management
- Neurocognitive diagnostics
- Precision medicine for Alzheimer’s and dementia
- Therapeutic plasma exchange
Key Technologies
- AI-driven diagnostics
- EEG-based brain mapping
- Live amyloid imaging
- Therapeutic plasma exchange
Key People
Chief Operating Officer
Chief Operating Officer
News & Updates
Local news feature highlights the launch and clinical innovation of the AI-guided Alzheimer’s clinic.
White paper explores advanced brain health therapies now being applied for cognitive optimization in professionals.
Overview of the integrated, personalized approach combining diagnostics, advanced therapies, and clinical protocols.
Case study and patient narrative demonstrating the impact of investigational monoclonal antibody therapy in Alzheimer’s disease.
Dr. David Wexler, a psychiatrist with over 20 years of experience in biological psychiatry and psychopharmacology, joins the advisory board to support neuropsychiatric management in Alzheimer's care.
Dr. Jason Hui joins as COO, bringing 18 years of experience in regenerative medicine and healthcare business strategy.
Local news feature highlights the launch and clinical innovation of the AI-guided Alzheimer’s clinic.
White paper explores advanced brain health therapies now being applied for cognitive optimization in professionals.
Overview of the integrated, personalized approach combining diagnostics, advanced therapies, and clinical protocols.
Case study and patient narrative demonstrating the impact of investigational monoclonal antibody therapy in Alzheimer’s disease.
Dr. David Wexler, a psychiatrist with over 20 years of experience in biological psychiatry and psychopharmacology, joins the advisory board to support neuropsychiatric management in Alzheimer's care.
Dr. Jason Hui joins as COO, bringing 18 years of experience in regenerative medicine and healthcare business strategy.